Aura Biosciences, Inc. (AURA)

Market Cap	437.08M
Revenue (ttm)	n/a
Net Income (ttm)	-83.22M
Shares Out	49.95M
EPS (ttm)	-1.72
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	247,563
Open	8.91
Previous Close	8.92
Day's Range	8.74 - 9.07
52-Week Range	6.63 - 12.38
Beta	0.33
Analysts	Strong Buy
Price Target	23.00 (+162.86%)
Earnings Date	Nov 12, 2024

About AURA

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company’s proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical develo...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 29, 2021
• Employees: 89
• Stock Exchange: NASDAQ
• Ticker Symbol: AURA
• Website: https://www.aurabiosciences.com

Analyst Forecast

According to 4 analysts, the average rating for AURA stock is "Strong Buy." The 12-month stock price forecast is $23.0, which is an increase of 162.86% from the latest price.

Price Target

$23.0

(162.86% upside)

Analyst Consensus: Strong Buy